Revolution Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for Revolution Medicines (RVMD).

Price Target Range — 8 Quarters

Analyst Consensus — 24 Analysts

1S.Buy

22Buy

1Hold

Consensus RatingBuy# Analysts24Avg. Consensus PT$191Upside to Avg. PT+0.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$251→$259
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$239→$240
Sep 28, 2026	Brookline Capital	Leah Rush	Initiate	Buy	$318
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$267
Sep 21, 2026	B of A Securities	Alec Stranahan	PT Raise	Buy	$225→$265
Sep 10, 2026	Morgan Stanley	Sean Laaman	Initiate	Overweight	$255
Sep 9, 2026	Stifel	Laura Prendergast	PT Raise	Buy	$215→$230
Aug 31, 2026	Needham	Ami Fadia	PT Raise	Buy	$240→$275
Aug 28, 2026	UBS	Michael Yee	PT Raise	Buy	$220→$265
Aug 28, 2026	Guggenheim	Michael Schmitz	PT Raise	Buy	$240→$275
Aug 27, 2026	Oppenheimer	Jay Olson	PT Raise	Outperform	$230→$260
Aug 27, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$203→$251
Aug 27, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$201→$225
Aug 27, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$231→$239
Aug 27, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$230→$320
Aug 27, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$195→$280
Aug 21, 2026	Bernstein	Jeffrey Walch	PT Raise	Market Perform	$151→$179
Aug 11, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$210→$231
Aug 6, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$182→$203
Aug 6, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$192→$201

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $259

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $251 to $259.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $239 to $240.

Benzinga Newsdesk

PRO
Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

Brookline Capital analyst Leah Rush initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $318.

Benzinga Newsdesk

PRO
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $267 price target.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265

B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $225 to $265.

Benzinga Newsdesk

PRO
Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255

Morgan Stanley analyst Sean Laaman initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announces Price Target of $255.

Benzinga Newsdesk

Revolution Medicines Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Revolution Medicines Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $259

PRO
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240

PRO
Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

PRO
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

PRO
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265

PRO
Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255

People Also Watch

People Also Watch

Revolution Medicines Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Revolution Medicines Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $259

PROTruist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240

PROBrookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

PROGoldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

PROB of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265

PROMorgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $259

PRO
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240

PRO
Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

PRO
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

PRO
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265

PRO
Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255